tp21 is your managing partner for your interdisciplinary research project, your multi-center clinical trial or your technology transfer plans.
You are planning to coordinate a European research project or a multi-center clinical study?
You coordinate a network or a medical association?
tp21 provides a full set of services to ...
BE-SAFE - Implementing a patient-centred and evidence-based intervention to reduce
BEnzodiazepine and sedative-hypnotic use to improve patient SAFEty and quality of care
Benzodiazepine and sedative hypnotics (BSHs) incur significant adverse effects and costs, especially in older adults.
Addressing BSH overuse in older adults is therefore an urgent priority to improve patient safety in Europe. However,
previous attempts did not lead to large-scale reduction in use.
The goal of BE-SAFE is to improve patient safety by addressing knowledge and practice gaps related to the reduction
of BSHs used for sleep difficulties in Europe.
Coordinated by Prof. Anne Spinewine, Université Catholique de Louvain, (BE), project management by tp21.
Duration: 5 years, starting 1 September 2022 - Total funding: approximately € 5.7 million.
eBRAIN-Health - Actionable Multilevel Health Data
Coordinated by Prof. Petra Ritter, CHARITE, project management by tp21.
Duration: 4 years, starting 1 July 2022 - Total funding: approximately € 13 million.
The project aims to develop a decentralized, data protection-compliant research platform capable of simulating some of the brain’s complex neurobiological phenomena. As part of the project, researchers will collate an array of different types of information, including data from PET and MRI scans, EEG tests, behavioral studies and lifestyle surveys, as well as clinical data from thousands of patients and healthy controls. These will be combined with biological information from knowledge databases and made available for research purposes. The resultant digital ‘brain twins’ will enable large numbers of researchers to conduct innovative research within a powerful digital infrastructure.
Thanks to its transparent analytical pipelines, the new research infrastructure will also help to promote reproducible research.
Furthermore, complex, personalized brain simulations which take into account large quantities of data may be able to provide a better understanding of the mechanisms underlying brain function and disorders. Virtual brain modeling may also improve diagnostics and disease prediction, in addition to enabling the optimization of treatment plans. The project consortium comprises 20 partners and operates in cooperation with EBRAINS AISBL, the coordinating entity of the EU-funded flagship ‘Human Brain Project’.
ENDOSCAPE will overcome a longstanding and major bottleneck in the field of gene delivery,
namely efficient, safe and cost-effective transfer of gene therapeutic products into the cytosol.
see Topics and Speakers
- Gene Therapy – Where We Stand Today
- Endosomal Escape – The Strategies
- Carriers of Endosomal Escape Enhancers and Genes
- Endosomal Escape – What Happens?
- GMP Production and Market
- Gene Therapy – Animal Experiments and Clinical Applications
- Poster sessions
- Christine Dufès, University of Strathclyde Glasgow
- Kazunori Kataoka, The University of Tokyo
- Fulvio Mavilio, Università degli Studi di Modena e Reggio Emilia
- Luigi Naldini, Università Vita-Salute San Raffaele Milano
- Jean-Philippe Pellois, Texas A&M University
- Pål Kristian Selbo, Oslo University Hospital
- Vladimir P. Torchilin, Northeastern Univerity Boston
- Jan van Hest, Eindhoven University of Technology
- Ernst Wagner, Ludwig-Maximilians-Universität München
- Inge Zuhorn, University Medical Center Groningen
The SYMPOSIUM is planned to be an onsite event at Berlin.
More details soon on the ENDOSCAPE website.
Please have a look at the >>ENDOSCAPE Video